Derek J. Maetzold Sells 1,947 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 1,947 shares of the company’s stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $20.35, for a total transaction of $39,621.45. Following the sale, the insider now owns 65,418 shares in the company, valued at $1,331,256.30. The sale was disclosed in a filing with the SEC, which is available at this link.

Castle Biosciences Trading Down 0.7 %

Shares of NASDAQ CSTL traded down $0.14 during midday trading on Wednesday, reaching $18.80. The company had a trading volume of 52,957 shares, compared to its average volume of 237,487. The business’s 50-day simple moving average is $21.81 and its 200 day simple moving average is $19.83. The stock has a market cap of $516.06 million, a P/E ratio of -8.77 and a beta of 0.93. Castle Biosciences, Inc. has a 1 year low of $9.26 and a 1 year high of $26.70.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Wednesday, February 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.74. Castle Biosciences had a negative net margin of 26.15% and a negative return on equity of 14.92%. The firm had revenue of $66.12 million during the quarter, compared to analysts’ expectations of $51.32 million. Analysts predict that Castle Biosciences, Inc. will post -2.41 earnings per share for the current year.

Analyst Ratings Changes

CSTL has been the topic of a number of recent analyst reports. KeyCorp increased their price objective on shares of Castle Biosciences from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, March 1st. Scotiabank upped their target price on shares of Castle Biosciences from $33.00 to $37.00 and gave the stock a “sector outperform” rating in a research note on Friday, March 1st.

Hedge Funds Weigh In On Castle Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. BluePath Capital Management LLC purchased a new position in Castle Biosciences in the 3rd quarter valued at $31,000. Royal Bank of Canada lifted its holdings in Castle Biosciences by 40.5% in the 2nd quarter. Royal Bank of Canada now owns 2,880 shares of the company’s stock valued at $39,000 after purchasing an additional 830 shares in the last quarter. O Dell Group LLC purchased a new position in Castle Biosciences in the 4th quarter valued at $44,000. Tower Research Capital LLC TRC lifted its holdings in Castle Biosciences by 61.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 1,821 shares of the company’s stock valued at $47,000 after purchasing an additional 691 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its holdings in Castle Biosciences by 37.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,626 shares of the company’s stock valued at $50,000 after purchasing an additional 984 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.